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Michael L. Marin, MD,a New York, NY
Objective: The management of renal artery stenosis in patients with abdominal aortic aneurysms continues to be complex
and technically challenging despite advances in endovascular therapy. There is growing concern about the durability of
renal artery stents in the setting of transrenal abdominal aortic endografts. This study reports a single-center experience
of renal artery stenting with transrenal abdominal aortic endografts for patients with renal artery stenosis.
Methods: All patients undergoing endovascular abdominal aortic aneurysm repair preceded or followed by renal artery
stent placement between January 1999 and December 2005 were retrospectively reviewed from a prospectively gathered
endovascular database. Patients were surveyed after renal stent procedures with multidetector computed tomography
angiography or duplex sonography. The surveillance data were analyzed for primary patency of the renal artery stent at
6 months, incidence of complications, need for secondary interventions, and changes in creatinine clearance (CrCl).
Results: Sixty-two renal artery stents were placed in 56 patients (44men, 12 women) with a mean age of 77.3 years (range,
61 to 94 years). Forty-one were placed before the endograft procedure, eight were placed during the endograft procedure,
and 13 were placed postoperatively. There were no major or minor complications related to the renal artery stent
procedures. Transrenal aortic endografts were used in 44 of the 56 patients, and 12 had devices with infrarenal fixation.
The mean follow-up was 18.5 months (range, 1 to 73 months). The 6-month primary patency, which could be evaluated
for 51 renal artery stents, was 97.4% (37/38) in patients with transrenal fixation and 84.6% (11/13) in patients with
infrarenal fixation. The overall rate of in-stent restenosis was 8.5% (4/47) in the transrenal fixation group and 20.0%
(3/15) in the infrarenal fixation group. The overall occlusion rate was 2.1% (1/47) in the transrenal fixation group and
0% (0/15) in infrarenal fixation group. Five (83.3%) of six patients underwent successful treatment of in-stent restenosis
with placement of a new stent in all five cases. CrCl decreased in the total group by 4.2  11.8 mL/min, by 4.7  12.0
mL/min in patients with transrenal fixation, and by 2.2  11.0 mL/min in patients with infrarenal fixation.
Conclusion: The presence of a transrenal aortic endograft did not affect the outcome of the renal artery revascularization
procedure in this cohort. Renal artery stenting in the presence of transrenal abdominal aortic endografts appears to be a
safe procedure without adverse effect on renal artery stent patency or renal function. (J Vasc Surg 2007;45:915-21.)Endovascular repair of abdominal aortic aneurysms
(AAAs) has evolved tremendously since the first aortic
endograft was implanted more than a decade ago.1 Ad-
vances in material and device manufacturing, together with
improvements in surgical technique, have expanded the
population of patients eligible for endovascular abdominal
aortic aneurysm repair (EVAR). The development of stent
grafts with an uncovered proximal landing zone allows
transrenal fixation across the renal arteries, thereby opening
endovascular doors for patients with short infrarenal necks.
Studies have shown promising results in these patients,
claiming adequate proximal fixation, no increased risk of
type I endoleaks, and no evidence of renal sequelae in
short-term follow-up.2-5 As the population of patients
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grows, new morphologic criteria continue to be reassessed
to determine the feasibility of EVAR in those aneurysms.
Patients with AAAs often have concomitant atheroscle-
rotic disease of their renal and iliac arteries. EVAR in a
patient with atherosclerotic, tortuous iliac vessels is associ-
ated with an increased complexity of the repair.6-8 To our
knowledge, however, how renal artery stenosis affects en-
dovascular repair has not been addressed in the literature.
In the past, patients with renal artery stenoses were
offered renal artery bypass or endarterectomy at the time of
their open AAA repair. Now, percutaneous treatment of
renal artery stenosis with angioplasty and stents is consid-
ered safe and effective.9-14 To decrease the risk of restenosis
of the renal artery, the stent needs to be placed 1 to 2 mm
into the aortic lumen to cover the renal ostium.12 Because
of the position of the renal artery stent in the aortic lumen,
one can postulate that difficulties can occur with transrenal
placement of endovascular stent grafts.
In addition to interfering with the placement of a
transrenal endograft, the presence of a renal artery stent in
the aorta adjacent to a transrenal endograft could poten-
tially interfere with the integrity of the renal artery stent and
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purpose of this study was to determine the effects of trans-
renal placement of endografts in patients with renal artery
stents.
METHODS
A retrospective review of a prospectively gathered en-
dovascular database was performed for all patients under-
going EVAR at our institution between January 1999 and
December 2005. Patients gave written informed consent
and were treated in accordance with the approval of the
Mount Sinai Medical Center Institutional Review Board.
All patients undergoing EVAR preceded or followed by
renal artery stent placement during this period were iden-
tified.
All patients underwent preoperative contrast-enhanced
computed tomography (CT) and arteriography to evaluate
AAA anatomy. Preoperative baseline serum creatinine (Cr)
levels were also obtained. Patients with chronic renal insuf-
ficiency (Cr 1.5 mg/dL) are hydrated with alkalinized
fluids for 2 to 4 hours before and after their CT angiogra-
phy (CTA) or arteriography imaging study.
Patients selected for renal artery stenting demonstrated
70% renal artery stenosis on selective arteriography in the
setting of clinical hypertension or renal insufficiency. Dur-
ing preoperative calibrated arteriography, asymptomatic
patients with 90% stenosis underwent renal artery stent
placement to protect against atheroembolic complications
during EVAR. Although this practice will not protect pa-
tients from smaller segmental infarctions, it should prevent
complete renal artery occlusion in this patient population.
Renal artery stents were placed intraoperatively in pa-
tients who had perceived coverage of the renal artery orifice
by the aortic endograft or as salvage procedures in patients
who had sustained embolic events. Renal artery stents were
placed after EVAR in patients who had progressive disease
that did not initially meet criteria preoperatively. Preoper-
ative treatment, when indicated, was preferred because of
the technical difficulties that may arise once a transrenal
endograft is in place.
All patients underwent percutaneous femoral or bra-
chial artery access under local anesthesia alone or combined
with conscious sedation. Brachial artery access was chosen
as the first-line access for patients who were treated after
EVAR. Once the renal artery was cannulated, before angio-
plasty and stent deployment, 3000 U of heparin was given
systemically.
Throughout the series, balloon-expandable stainless
steel renal artery stents were used. Initially, the Corinthian
0.035-inch (Cordis/Johnson & Johnson, Warren, NJ) sys-
tem was used, and later, the Genesis 0.014-inch (Cordis/
Johnson and Johnson) system was used.
All patients underwent a completion renal angiogram
that confirmed stent placement and resolution of the ste-
nosis. If a residual narrowing remained after stent deploy-
ment, the stent was postdilated until an acceptable lumen
was demonstrated.All EVAR procedures were performed in the operating
room under spinal anesthesia with portable C-arm fluoros-
copy. Access to the arterial system was through a cutdown
across one or both femoral arteries. Completion angio-
grams were obtained in all patients after deployment of the
stent graft to confirm aneurysm exclusion and renal artery
patency.
Follow-up for all patients undergoing EVAR consisted
of an office visit with the operating surgeon as well as plain
abdominal radiography and three-phase contrast-enhanced
CTA at 1 month, 6 months, 12 months, and annually
thereafter. Patients were surveyed after renal stent proce-
dures with CTA and duplex sonography imaging along
with measurements of serum creatinine. The surveillance
data were analyzed for primary patency of the renal artery
stent at 6 months, incidence of complications, need for
secondary interventions, and changes in creatinine clear-
ance (CrCl), which was estimated using the Cockcroft-
Gault formula: CrCl  (140–age)  weight/(SCr  72),
which was adjusted for women by multiplying the result by
0.85.15 This formula was selected as a simple means of
standardizing renal function by weight, gender, and age,
although it is known to overestimate glomerular filtration
rate.16
Statistical analysis was performed using SPSS 14.0 sta-
tistical software (SPSS Inc, Chicago, Ill) and GraphPad
Prism (GraphPad Software, Inc, San Diego, Calif). Data
were expressed as mean  standard deviation. Continuous
variables were compared using the Student t test. Univari-
ate analysis of categoric variables was performed with the
Fisher exact test or 2 analysis when appropriate. Differ-
ences were considered significant at P  .05.
RESULTS
During the period reviewed, 924 EVARs were per-
formed at our institution in which 56 patients (6.1%) had
renal artery stents placed. This cohort was a mean age of
77.3 7.3 years and included 44 men (78.6%) and 12
women (21.4%). Two patients had previously undergone
nephrectomies for malignancy, and two patients had
chronic unilateral renal artery occlusion.
Sixty-two renal artery stents were placed in these 56
patients, including 50 patients who had unilateral stent
placement and six who had bilateral stent placement. The
timing of stent placement included 41 stents (66.1%) in-
serted before the EVAR procedure, eight (12.9%) inserted
during the EVAR procedure, and 13 (21.0%) placed after
EVAR (Fig 1 and Fig 2). Asymptomatic high-grade renal
artery stenoses were present in 11 of the 39 patients who
underwent renal artery stenting before EVAR, and 28 had
chronic renal insufficiency (Cr 1.5 mg/dL) along with
some degree of hypertension. The six patients treated in-
traoperatively all had perceived flow-limiting coverage by
the aortic endograft or atheroemboli. Four of the 11 pa-
tients treated after EVAR had uncontrolled hypertension,
and seven had a combination of renal insufficiency and
hypertension.
device.
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the renal artery stent procedures. Transrenal aortic en-
dografts were placed in 44 (78.6%) of the 56 patients, and
infrarenal fixation devices were used in 12 (21.4%). The 44
transrenal endografts included 37 Talent (Medtronic
World Medical, Sunrise, Fla) devices, two Cordis (Cordis/
Johnson and Johnson) devices, two Zenith (Cook, Bloom-
ington, Ind) devices, and three homemade custom-made
Parodi (Johnson & Johnson, Sommerville, NJ)/Palmaz
(Impra, C. R. Bard, Murray Hill, NJ) devices. The 12
devices with infrarenal fixation included seven Gore (W. L.
Gore & Associates, Flagstaff, Ariz) devices and five Aneurx
(Medtronic/AVE, Santa Rosa, Calif) devices. The config-
urations for these devices included 40 bifurcated devices,
12 aortouniiliac devices, and four aortoaortic tube devices.
The mean follow-up was 18.5  18.6 months. Six-
month primary patency, which could be evaluated for 51
renal artery stents, was 97.4% (37/38) in patients with
transrenal fixation and 84.6% (11/13) in patients with
infrarenal fixation. No statistically significant difference was
noted in 6-month patency between the two groups (P 
.16). All three stents that developed restenosis within 6
months were successfully treated with secondary angio-
plasty and stenting. The overall rate of in-stent restenosis
for the 62 renal artery stents was 8.5% (4/47) in the
transrenal fixation group and 20.0% (3/15) in the infrare-
nal fixation group. In-stent restenosis between the two
groups was not statistically significant (P  .35). Six
(85.7%) of seven patients underwent successful treatment
of in-stent restenosis with placement of a new stent.
One of these patients initially underwent secondary
Fig 2. Balloon angioplasty of a renal artery stent through the
transrenal struts of a Talent endograft.Fig 1. A, Preoperative angiogram demonstrates a 5.9-cm ab-
dominal aortic aneurysm and50% left renal artery stenosis.B, An
angiogram obtained 18months after endovascular aneurysm repair
with a Talent aortouniiliac device demonstrates severe left renal
artery stenosis.C, Completion angiogram demonstrates successful
renal artery stenting through the transrenal struts of the Talentangioplasty and stenting 7 months after his initial renal
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months later, and finally, angioplasty and stenting 6
months after that. The patient who was unable to undergo
successful treatment of his in-stent restenosis had a chron-
ically occluded left renal artery and underwent successful
stenting of his right renal artery before EVAR. He was
readmitted 8 months after his EVAR with acute renal
failure at which time an attempt was made to recanalize his
right renal artery. This was unsuccessful. The patient re-
fused dialysis and later died.
The overall occlusion rate was 2.1% (1/47) in the
transrenal fixation group and 0% (0/15) in the infrarenal
fixation group (P  1.0). Survival-curve analysis estimated
that approximately 80% of patients with renal artery stents
who underwent EVAR will be free from stent occlusion or
in-stent restenosis at 24 months (Fig 3).
Twenty-one patients (37.5%) had baseline renal insuf-
ficiency (serum creatinine 1.5 mg/dL), including 17
(38.6%) of 44 patients in the transrenal fixation group and
four (33.3%) of 12 in the infrarenal fixation group. Baseline
CrCl was not significantly different between those patients
who underwent EVAR with transrenal fixation devices and
those who had infrarenal fixation devices (54.5  27.0
mL/min vs 49.1  18.3 mL/min, P  .52). CrCl de-
creased in the overall group by 4.2 11.8 mL/min during
the follow-up period, from 53.3 25.3mL/min to 49.2
23.6 mL/min. CrCl decreased by 4.7  12.0 mL/min in
patients with transrenal fixation devices and by 2.2  11.0
mL/min in patients with infrarenal fixation devices. There
was no statistically significant difference in change in CrCl
between the two groups (P  .53; Fig 4).
In seven patients (12.5%), the decrease in CrCl was
30% of their baseline, including five (11.4%) of 44 pa-
tients in the transrenal fixation group and two (16.7%) of
12 in the infrarenal fixation group. Five of these patients
had baseline renal insufficiency. Only one went on to
require dialysis, which as aforementioned, the patient re-
Fig 3. Survival curve demonstrates freedom from renal artery
stent occlusion and in-stent restenosis in patients with renal artery
stents and aortic endografts.fused.DISCUSSION
Ever since being first described more than 15 years ago,
EVAR has emerged as an excellent alternative to open
repair of AAAs.1 Despite the popularity of the procedure,
only a certain percentage of patients with AAAs are candi-
dates for this form of therapy. Anatomic limitations, such as
an angulated or short proximal infrarenal implantation site,
can place a patient at risk for postoperative complications
that include endoleak, aneurysm sac enlargement, and even
aneurysm rupture.
Suprarenal fixation has been proposed as an effective
solution to overcome the anatomic constraints of certain
AAAs, particularly with respect to the proximal seal zone.2
Suprarenal fixation has been theorized to increase patient
eligibility and prevent late device migration and en-
doleak.17 Some studies have suggested improved outcomes
with suprarenal fixation by decreasing the incidence of late
endoleaks.18 Many authors have reported excellent imme-
diate and intermediate results with these devices. There still
exists a sense of concern about the effects on the renal
arteries and renal parenchyma in the setting of bare metal
struts crossing the origins of the renal arteries.19
Most studies that have analyzed the effect of suprarenal
fixation compared with infrarenal fixation on renal function
have shown no differences between the two groups.2,4,5
Furthermore, one study has shown that the impact of a
suprarenal endograft on renal function is not dissimilar
from the impact of a standard open repair on renal func-
tion.20 One of the comparative studies demonstrated a
significant increase in the incidence of postoperative renal
impairment in the suprarenal fixation group compared with
the infrarenal fixation group.21 The mechanism for these
Fig 4. Changes in creatine clearance (CrCl) in patients with renal
artery stents and infrarenal vs transrenal aortic endografts during
the follow-up period. Data are presented as mean  standard
deviation.observations is unclear.
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fects observed in the renal parenchyma after EVAR that
would suggest an atheroembolic potential of the EVAR
procedure.22 Another potential risk would be the exacer-
bation of an atherosclerotic narrowing in the presence of
suprarenal fixation, which has been suggested by previous
studies.
Lobato et al19 reported a patient with a suprarenal
aortic endograft and 60% renal artery stenosis which pro-
gressed to 99% at 4 months after EVAR. Bove at al3 also
observed the progression of an ostial renal artery stenosis in
the setting of suprarenal fixation.
Lau et al23 reported a single-center experience in the
use of aortic endografts with suprarenal fixation and com-
pared those results with the same center’s experience with
infrarenal devices. No difference was noted in renal func-
tion between the two groups at 12 months in their study,
but two renal artery occlusions were observed in the supra-
renal fixation group and none in the infrarenal fixation
group. It was mentioned that these two patients had previ-
ously observed ostial atherosclerotic narrowings50% that
were not revascularized before EVAR. These authors rec-
ommended caution when supernal fixation is considered in
patients with pre-existing atherosclerotic renal artery steno-
sis.
Recent studies have attempted to quantitate the
amount of coverage of the renal artery ostia created by
transrenal fixation of an aortic endograft. England et al24
used three-dimensional CT reconstruction software to cre-
ate virtual intravascular endoscopies of 55 patients who
underwent EVAR with Talent aortic endografts. In their
study, only 40% of patients had a stent strut cross a renal
artery unilaterally, and 9% had stent struts crossing both
renal artery ostia. The incidence of renal artery coverage did
not affect renal function.24
Another study by Sun et al25 demonstrated 90% of
renal artery ostia to be involved by the suprarenal struts of
the Zenith device.Most of the cases presented in their series
were repaired using the Talent aortic endograft, which has
a unique design compared with other aortic devices with
suprarenal fixation. One specific characteristic is the lack of
fixation hooks compared with the Zenith device. Another
characteristic is the relative wide spacing and fewer num-
bers of suprarenal struts compared with the Zenith device.
The Zenith device is not used routinely at our institution,
and their series has limited relevance for patients treated
with that specific device design.
Recently, there has been great interest in the applica-
bility of EVAR for patients with juxtarenal or pararenal
aneurysms. Feasibility studies have been published on the
use of fenestrated Zenith devices for the treatment of these
patients.26 In these cases, the fabric of the endovascular
device is implanted higher than the renal artery ostia, with
scallops or fenestrations created to allow perfusion of the
kidneys. These openings are secured in place with translu-
minally placed renal artery stents at the time of the aortic
repair.Although these studies have demonstrated feasibility,
there appears to be significant renal effects with these
devices encroaching fabric on the renal artery ostia, in some
instances circumferentially. In a series of 72 patients,
Haddad et al27 reported an overall incidence of significant
renal function deterioration of 33%. The major risk factor
for this outcome was pre-existing renal dysfunction with an
estimated glomerular filtration rate of 60 mL/min. Ad-
verse renal events in this cohort included renal artery ste-
nosis, renal artery occlusion, and renal failure requiring
dialysis.
CONCLUSIONS
The early results of the use of renal artery stents in
fenestrated aortic endografts are discouraging and should
be viewed with caution. The series presented here did not
have the same incidence of adverse outcomes. One expla-
nation may be the use of different endografts. In particular,
a large number of patient in this series were treated with
Talent endografts, which are not currently approved for use
by the United States Food and Drug Administration. An-
other may be the intrinsic difference between a device with
a suprarenal bare stent and one with suprarenal fabric and
renal fenestrations.
To our knowledge, this is the first study to review a
series of renal artery stents placed for atherosclerotic ostial
stenoses in the presence of a suprarenal aortic endograft.
These results offer preliminary evidence to support the use
of this technology without risks of significant adverse
events. The incidence of adverse stent associated events
including in-stent stenosis and stent occlusion were similar
to previously published series on renal artery ostial stenting
for atherosclerotic lesions.
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Dr Michael J. Costanza (Syracuse, NY). Dr Baril and the
Mount Sinai group have addressed an important problem that
virtually every vascular specialist has faced: how to manage renal
artery stenosis in a patient awaiting or undergoing an endovascular
abdominal aortic aneurysm repair. The decision-making on these
patients can be challenging for several reasons, which you have
clearly outlined in your paper.
Your results indicate that renal artery stenting before, during
and after EVAR is feasible even with transrenal fixation devices. I
am convinced that we can perform renal artery stenting in these
patients, but I’d like you to tell us if we should be doing this.
My first question is about the natural history of renal artery
stenosis and EVAR. Have you looked at your center’s over 900
endovascular aneurysm repairs to identify and track patients with
renal artery stenosis who are managed medically after their EVAR?
This information would be helpful in determining how aggres-
sively we should look for and treat renal artery stenosis in these
patients.
Secondly, did renal artery stenting confer any clinical benefits
for these treated patients? Was their blood pressure controlled withAlthough you did not detect a change in creatinine clearance in
your series, creatinine can be an insensitive indicator for renal
function. Also, only a third of your patients had renal insufficiency,
which implies that the majority of patients either were hypertensive
or asymptomatic.
And finally, detailed CT scans and CT angiograms have made
preoperative angiography unnecessary for many patients awaiting
EVAR. How would you suggest that these patients be managed
with respect to evaluating them for renal artery stenosis? Is it
reasonable to identify and treat renal artery stenosis at the time of
an endovascular aneurysm repair or should they be treated in a
staged fashion?
Dr Donald T. Baril. In reference to your first question, as to
whether we have looked at the natural history of renal stenosis in
these patients, we have previously, and observed that essentially
patients with renal artery stenosis with a transrenal aortic endograft
tend to have the same natural course as if the graft is not there.
They have progression of the disease, but not at a rate higher than
would be expected without the presence of the endograft.
That being said, the patients that we choose to place renal
artery stents in preoperatively are those that have high-grade
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concern of atheroembolic events at the time of aortic endograft
deployment.
Additionally, patients with 70% or greater stenosis in the
setting of clinical hypertension or renal insufficiency have also been
stented.
In reference to your second question of the clinical benefits,
that was not specifically examined in this series. There are anecdotal
reports from our own institution that some patients have been
weaned off antihypertensives whereas others have continued to
require equal or greater doses. However, the patients with renal
insufficiency who underwent renal artery stenting have basicallyFinally, in reference to your last question, our institution has
continued to do preoperative angiography for a number of differ-
ent reasons. One is the belief that this is the best means of
measuring aneurysm and aortic length. Additionally, a large num-
ber of our cases are referred to our tertiary referral center and
require adjuvant therapy, whether it be a renal artery stent or
hypogastric embolization, before endograft deployment.
That being said, if a renal artery lesion is found on CT
angiography, the next step would be to perform a renal artery
duplex to determine the clinical significance of the stenosis. Based
on the results of the duplex, we would recommend a staged
procedure to minimize operative time as well as contrast load inmaintained their renal function. what is often a renal insufficient population.
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